5 Biggest Genomics Companies In The World

4. CRISPR Therapeutics AG (NASDAQ:CRSP)

Market Capitalization: $4.10 billion

Number of Hedge Fund Holders: 25

Incorporated in 2013, CRISPR Therapeutics AG (NASDAQ:CRSP) produces radical gene-based medicines to treat serious diseases through its proprietary gene editing technology called the CRISPR/Cas9 platform. The firm’s diverse portfolio of therapeutics serves a vast array of diseases across four key franchises:  hemoglobinopathies, immuno-oncology, regenerative medicine, and rare diseases. Headquartered in Zug, Switzerland, the company has its operation network across Switzerland, the US, and the UK.

On August 09, 2022, Benjamin Burnett, an analyst at Stifel, increased his target price to $69 from $55. The analyst believes that the approval of exa-cel in SCD and beta-thalassemia is likely; however, he remains cautious about the company’s gen CAR-T programs, which is why he keeps a Hold rating on the stock.

As per Insider Monkey database, 25 hedge funds remained bullish on the company’s stock at the end of Q2 2022. ARK Investment Management held the highest stake in the company during Q2 2022, with an investment value of over $564 million.